Brief: Cema-Cel Pivotal Trial Interim Data Highlight Strength Of Cellectis’ Allogeneic Car-T Platform
13/04/2026 22:06
April 13 (Reuters) - Cellectis SA ALCLS.PA: CEMA-CEL PIVOTAL TRIAL INTERIM DATA HIGHLIGHT STRENGTH OF CELLECTIS’ ALLOGENEIC CAR-T PLATFORM CELLECTIS SA - CEMA-CEL TREATMENT GENERALLY WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED CELLECTIS SA: STUDY ACCRUAL EXPECTED TO BE COMPLETE BY 2027 END & IT ANTICIPATES INTERIM EFS ANALYSIS IN MID-2027 & PRIMARY EFS ANALYSIS IN MID-2028 Source text: ID:nGNX6hSxwJ Further company coverage: ALCLS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cellectis SA
See all newsNASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:05 AM
Brief: Cellectis Receives FDA Rmat Designation For Lasme-Cel, The First Allogeneic Car-T Therapy In A Pivotal Trial For Patients With R/R B-All
Brief: Cema-Cel Pivotal Trial Interim Data Highlight Strength Of Cellectis’ Allogeneic Car-T Platform
France's Cellectis swings to net loss in Q4
Brief: Cellectis Q4 Operating Income USD -17.352 Million